Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 3/2017

THE IMPACT OF COMBINED ADMINISTRATION OF SEROTONIN-SPECIFIC REUPTAKE INHIBITORS WITH ATORVASTATIN ON THE LIVER AND KIDNEYS. IN VITRO AND IN VIVO STUDIES

MARIOLA HERBET, MAGDALENA IZDEBSKA, MONIKA GAWROŃSKA-GRZYWACZ*, IWONA PIĄTKOWSKA-CHMIEL, JAROSŁAW DUDKA

Department of Toxicology, Medical University of Lublin, 8B Jaczewski Street, Lublin 20-090, Poland

Download Full Article PDF

In the treatment of depression coexisting with cardiovascular disease, serotonin-specific reuptake inhibitors (SSRIs) are the most frequently prescribed in combination with statins used for treating hypercholesterolemia in the primary and secondary prevention of cardiovascular and cerebrovascular incidents. Because of a risk of adverse interactions between above-mentioned drugs, our research was aimed to assess the impact of combined administration of SSRIs (fluoxetine or paroxetine) and atorvastatin on the physiological kidney cell culture and the functions of liver and kidneys in rats. The results of in vitro assays suggest an adverse effect of combination of fluoxetine and atorvastatin on cell viability. Conversely, the results of in vivo experiments indicate this combination superior safety profile in comparison to atorvastatin coupled with paroxetine. The adverse effect observed may point out the possibility of minor liver and kidney disorders during the long-term treatment with paroxetine and atorvastatin.